Unbiased high-throughput screening of drug-repurposing libraries identifies small-molecule inhibitors of clot retraction.

ABSTRACT:

Abstract

Platelet clot retraction, the ultimate phase of platelet thrombus formation, is critical for clot stabilization. It requires functional αIIbβ3 receptors, fibrin, and the integrated actions of the actin-myosin contractile and cytoskeletal systems. Disturbances in clot retraction have been associated with both bleeding and thrombosis. We recently demonstrated that platelets treated with the αIIbβ3 antagonist peptide Arg-Gly-Asp-Trp, which eliminates fibrinogen-mediated platelet aggregation, are still able to retract clots. We have exploited this observation to develop an unbiased, functional high-throughput assay to identify small-molecule inhibitors of fibrin-mediated clot retraction adapted for a 384-well plate format. We tested 9710 compounds from drug-repurposing librari

SUBMITTER: Buitrago L 

PROVIDER: S-EPMC11909436 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature